Five things for pharma marketers to know: Thursday, January 4, 2018

Share this content:

1. Allergan plans to cut more than 1,000 jobs, as it braces itself for competition from a generic version of its blockbuster dry-eye treatment Restasis this year. (Bloomberg)

2. Pharmaceutical distributor McKesson Corporation acquired pharmacy services provider RxCrossroads from CVS Health. The purchase price was $735 million. (Drug Store News)

3. Pfizer will pay Sangamo Therapeutics $12 million upfront and $150 million in milestones to collaborate on the development of a gene therapy to treat ALS. (Endpoints News)

4. Novartis' Promacta received Breakthrough Therapy Designation for first-line treatment of severe aplastic anemia, a rare blood disorder. Promacta first received FDA approval in 2008, when it was marketed by GlaxoSmithKline. (Reuters)

5. The Philippines fined Sanofi $2,000 and suspended the drugmaker's certificate of product registration for dengue vaccine Dengvaxia. The certificate suspension prevents the drugmaker from selling, distributing, and marketing the vaccine in the country. (Reuters)

Share this content:
Scroll down to see the next article